The Opportunity Map
Where did radiopharma's money go, and why did so little of it reach the layers every dose depends on?
Radiopharma is no longer short of money. Between 1 January 2024 and 26 October 2026, ProGen records 231 acquisitions, financings and credit commitments in the sector, 126 with a disclosed figure. The question is not whether capital is arriving. It is where it lands, and whether that is where the bottlenecks are.
Research cut-off: 26 October 2026
What this report answers
- Where did radiopharma's capital go between January 2024 and October 2026, layer by layer?
- What did the largest acquisitions of 2024 and of 2026 actually buy?
- Who funds isotope production, and with what kind of money?
- Why do equipment, contract manufacturing and specialist clinical services show so little disclosed capital?
- Where should diligence look first for opportunity the capital record has not yet caught up with?
- What would prove ProGen's four forecasts wrong?
231 transactions
Acquisitions, financings and credit commitments in radiopharma, 1 January 2024 to 26 October 2026. 126 carry a disclosed figure.
$17.0bn | $5.2bn | $0.5bn
Acquisition consideration (ceilings included), primary financing and credit commitments. Three separate classes of capital, never added together.
What the analysis establishes
The money that is raised goes to drug developers
Developers and sponsors account for 122 of the 231 transactions, 105 of the 137 primary financings and $4.1 billion of the $5.2 billion of disclosed financing. Recorded developer financing is highest in 2026 year to date, with public offerings alongside large private rounds.
The money that is spent on acquisitions has changed target
In 2024 the largest acquisitions bought pipelines: AstraZeneca's purchase of Fusion Pharmaceuticals and Novartis's purchase of Mariana Oncology. In 2026 the largest acquisitions bought platforms that already existed: Curium and Lantheus, Telix and ITM, GE HealthCare and SOFIE, Nordic Capital and BWXT Medical.
Isotope production is funded by strategics, credit and consolidation alongside private rounds
Of the nine isotope-production transactions with a disclosed value, six are acquisitions or debt. A pharma group, the US Department of Energy, specialist credit funds and private equity buyers appear where growth-equity investors are thinly represented.
The layers in between serve demand that recorded capital does not match
Equipment and infrastructure, contract manufacturing and specialist clinical services together account for 59 transactions but only 16 disclosed figures. The demand they serve shows up elsewhere: 28 late-stage trials active or planned in the publicly reportable subset, and hiring signals tracked between May and mid October 2026 concentrated at isotope producers. Part of that invisibility may be disclosure and tracking rather than absence, and the report says where.
Where to look: four diligence priorities
ProGen presents four priorities for diligence, ordered by judgment, not by a score: feedstock and precursor supply; the delivery layer of radiopharmacies, Class 7 logistics, treatment-site networks and dosimetry; independent therapeutic manufacturing able to run alpha emitters under aseptic rules with a clean inspection record; and equipment, automation and rapid-release quality control. Developers and diagnostics rank last for new money.
The capital funds the factory
The people who run it, the qualified persons who release a batch against a decay clock, the nuclear pharmacists, the authorized users, the physicists, the engineers who qualify a shielded suite, take years to train, and no transaction buys them. Across the map, the roles most sought are in production operations, radiochemistry, quality control and engineering. ProGen's reading, offered as a hypothesis the hiring data cannot by itself prove, is that workforce is a binding constraint across the supply layers and the one least visible in the capital record.
About this intelligence
Counts of transactions, trials and hiring signals are ProGen Search tracking as at 26 October 2026, and counts of organizations as at 28 October 2026, built from public registries, company announcements, regulatory filings and proprietary ProGen intelligence sources. Transaction figures are as announced, converted to US dollars at approximate rates, with acquisition consideration, primary financing and credit commitments reported separately and never added together. Interpretation is labeled ProGen reading. Nothing in this report is investment advice.
Who it is for
Investors, corporate development teams and leadership teams at radiopharma developers, isotope producers, contract manufacturers, equipment makers and clinical service firms who need to know where capital has gone in the value chain and where it has not.
What you can use
- Disclosed capital by layer and class across the eight layers of the value chain, with coverage beside every number.
- Acquisitions and primary financing by year, developers against everyone else.
- Every disclosed isotope-production transaction in the window, by instrument.
- Four diligence priorities, ordered by judgment.
- Four forecasts, each with the evidence that would prove it wrong.
Contents
- Executive summary
- The question
- The method
- Where the money went
- What the money bought
- The eight layers, as a journey
- Why the money is not where the gap is
- Where to look: four diligence priorities
- Four forecasts, with what would prove them wrong
- Limits
- About this intelligence and public sources
Transactions discussed
Curium and Lantheus, Telix and ITM, GE HealthCare and SOFIE, Nordic Capital and BWXT Medical, AstraZeneca and Fusion Pharmaceuticals, Novartis and Mariana Oncology
The full 15-page briefing is free. Tell us where to send it and it downloads immediately.
About ProGen
Byron Fitzgerald, founder of ProGen Search, places VP to C-suite leaders across operations, manufacturing, quality and commercial functions in radiopharma and complex modalities, and publishes the market intelligence behind those searches.
Market and competitor mapping around a defined investment, partnering or manufacturing decision.
Leadership searches for the supply layers, where the people who run the factory take years to train.